Drug Development of Choroideremia Pipeline Report Analysis
09 Sep 2021
Gene TherapyAntibodySmall molecular drug
Los Angeles, USA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Drug Development of Choroideremia Pipeline Report Analysis | DelveInsight
The need for a new therapeutic option is acute. Clinical research is underway investigating the gene therapies for the effective treatment of Choroideremia.
DelveInsight’s “Choroideremia Pipeline Insight” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Choroideremia pipeline landscapes. It comprises Choroideremia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Choroideremia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Choroideremia pipeline products.
Some of the key takeaways from the Choroideremia Pipeline Report
Get an overview of pipeline landscape @ Choroideremia Clinical Trials Analysis
Choroideremia is a rare genetic disorder of vision that is more common in men. It is an X-linked recessive condition that gradually degrades the choroid, retinal pigment epithelium (RPE), and photoreceptors.
Choroideremia Emerging Drugs
NightstaRx Ltd initiated the development of BIIB111 for the treatment of Choroideremia. BIIB111 is a gene therapy-based treatment consisting of AAV2 vectors with recombinant human DNA designed to deliver REP1 protein to the retina.
Spark Therapeutics is advancing an open-label, dose-escalating Phase I/II trial designed to assess the safety and preliminary efficacy of subretinal administration of investigational SPK-7001. Each of the investigational research programs uses an adeno-associated viral (AAV) vector developed and manufactured by the Spark team and their collaborators.
For further information, refer to the detailed report @ Choroideremia Pipeline Therapeutics
Scope of Choroideremia Pipeline Drug Insight
· Choroideremia Therapies Late-stage (Phase III) · Choroideremia Therapies Mid-stage (Phase II)· Choroideremia Therapies Early-stage (Phase I) · Choroideremia Preclinical stage and Discovery candidates · Discontinued and Inactive candidates
· Gene transference· CHM protein expression stimulants; Gene transference· Gluconeogenesis inhibitors· CHM protein expression stimulants; Gene transference
· Peptides· Monoclonal antibodies· Small molecules · Polymer · Gene therapy
· Parenteral · Intravitreal· Oral· Subretinal
· Monotherapy· Combination· Mono/Combination
Key Questions regarding Current Choroideremia Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customized pipeline report @ Choroideremia Drugs Pipeline Report
Other Reports
Browse Blog Posts
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.